6185: CanSino Biologics Inc. - Summary | Jitta

CanSino Biologics Inc.

HKG:6185

Price
HK$42.00
Loss Chance
58.1%
0.96JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
182 / 192
2,231 / 2,389
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (11)
Recent Business Performance (11)
Financial Strength (43)
Return to Shareholders (17)
Competitive Advantage (18)
Jitta Signs
SG&A to SalesDecreasing
Revenue and EarningEarning loss detected in 2022
Operating MarginDeclined
Recent Business PerformanceEarning decline 172.17% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
Key Stats
Jitta Score
Jitta Line
0.96
100.00%
4.56
129.25%
3.58
245.67%
Pharmaceuticals
7.02
26.54%
6.74
69.77%
7.55
56.16%
COMPANY DESCRIPTION
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People’s Republic of China.